Answer
Enrylaze (recombinant crisantaspase) should not be used during pregnancy unless the woman's clinical condition requires treatment and justifies the potential foetal risk, as human pregnancy data are unavailable and animal studies indicate potential embryonic and foetal harm.
Sources for this answer
- Enrylaze 10 mg/0.5 ml Solution for injection/infusionJazz Pharmaceuticals UK Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 2Document updated
Sources checked